During the last session, Compass Therapeutics Inc (NASDAQ:CMPX)’s traded shares were 0.58 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $1.09, reflecting an intraday gain of 7.92% or $0.08. The 52-week high for the CMPX share is $2.66, that puts it down -144.04 from that peak though still a striking 30.28% gain since the share price plummeted to a 52-week low of $0.76. The company’s market capitalization is $149.97M, and the average intraday trading volume over the past 10 days was 0.56 million shares, and the average trade volume was 382.42K shares over the past three months.
Compass Therapeutics Inc (CMPX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.43. CMPX has a Sell rating from 1 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Compass Therapeutics Inc (CMPX) registered a 7.92% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.92% in intraday trading to $1.09, hitting a weekly high. The stock’s 5-day price performance is 9.49%, and it has moved by 4.81% in 30 days. Based on these gigs, the overall price performance for the year is -58.56%. The short interest in Compass Therapeutics Inc (NASDAQ:CMPX) is 2.02 million shares and it means that shorts have 4.04 day(s) to cover.
Compass Therapeutics Inc (CMPX) estimates and forecasts
Statistics show that Compass Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Compass Therapeutics Inc (CMPX) shares have gone down -24.83% during the last six months, with a year-to-date growth rate less than the industry average at -18.18% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.88%. While earnings are projected to return -17.17% in 2024.
CMPX Dividends
Compass Therapeutics Inc is due to release its next quarterly earnings 2024-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
Compass Therapeutics Inc insiders own 12.04% of total outstanding shares while institutional holders control 74.57%, with the float percentage being 84.77%. ORBIMED ADVISORS LLC is the largest shareholder of the company, while 107.0 institutions own stock in it. As of 2024-03-31, the company held over 22.36 million shares (or 17.55% of all shares), a total value of $44.28 million in shares.
The next largest institutional holding, with 11.13 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 8.7346% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $22.04 million.
Also, the Mutual Funds coming in first place with the largest holdings of Compass Therapeutics Inc (CMPX) shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . Data provided on Jun 30, 2024 indicates that iShares Russell 2000 ETF owns about 2.38 shares. This amounts to just over 4.57 percent of the company’s overall shares, with a $2.6 million market value. The same data shows that the other fund manager holds slightly less at 2.19, or about 4.20% of the stock, which is worth about $2.39 million.
